EUVIMEDEUVIMED entdecken
Klinische StudieOpen Access

Glycemic Outcomes During Early Use of the MiniMed™ 780G Advanced Hybrid Closed-Loop System with Guardian™ 4 Sensor

Toni L Cordero iD, Zheng Dai, Arcelia Arrieta, Fang Niu, Melissa Vella, John Shin, Andrew S Rhinehart, Jennifer McVean, Scott W Lee, Robert H Slover, Gregory P Forlenza iD, Dorothy I Shulman und 9 weitere

Diabetes Technology & Therapeutics · 2023

DOI: 10.1089/dia.2023.0123 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift Diabetes Technology & Therapeutics, 2023. Verfasst von Toni L Cordero und 20 weiteren Autor:innen. Beteiligte Einrichtung: Medtronic, Northridge, California, USA. Hauptthemen laut MEDLINE: Blood Glucose, Diabetes Mellitus, Type 1. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Safety and significant improvement in overall glycated hemoglobin (A1C) and percentage of time spent in (TIR), below (TBR), and above (TAR) glucose range were demonstrated in the pivotal trial of adolescents and adults using the MiniMed™ advanced hybrid closed-loop (AHCL) system with the adjunctive, calibration-required Guardian™ Sensor 3. The present study evaluated early outcomes of continued access study (CAS) participants who transitioned from the pivotal trial investigational system to the approved MiniMed™ 780G system with the non-adjunctive, calibration-free Guardian™ 4 Sensor (MM780G+G4S). Study data were presented alongside those of real-world MM780G+G4S users from Europe, the Middle East, and Africa.

Methods

The CAS participants (N = 109, aged 7-17 years and N = 67, aged >17 years) used the MM780G+G4S for 3 months and data of real-world MM780G+G4S system users (N = 10,204 aged ≤15 years and N = 26,099 aged >15 years) were uploaded from September 22, 2021 to December 02, 2022. At least 10 days of real-world continuous glucose monitoring (CGM) data were required for analyses. Glycemic metrics, delivered insulin and system use/interactions underwent descriptive analyses.

Results

Time in AHCL and CGM use were >90% for all groups. AHCL exits averaged 0.1/day and there were few blood glucose measurements (BGMs) (0.8/day-1.0/day). Adults in both cohorts met most consensus recommendations for glycemic targets. Pediatric groups met recommendations for %TIR and %TBR, although not those for mean glucose variability and %TAR, possibly due to low use of recommended glucose target (100 mg/dL) and active insulin time (2 h) settings (28.4% in the CAS cohort and 9.4% in the real-world cohort). The CAS pediatric and adult A1C were 7.2% ± 0.7% and 6.8% ± 0.7%, respectively, and there were no serious adverse events.

Conclusions

Early clinical use of the MM780G+G4S was safe and involved minimal BGMs and AHCL exits. Consistent with real-world pediatric and adult use, outcomes were associated with achievement of recommended glycemic targets. Clinical Trial Registration number: NCT03959423.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Blood GlucoseDiabetes Mellitus, Type 1AdolescentAdultChildHumansBlood Glucose Self-MonitoringGlucoseGlycated HemoglobinHypoglycemic AgentsInsulinInsulin Infusion Systems

Stichwörter der Autor:innen

Advanced hybrid closed-loopGlucose sensorNon-adjunctiveReal-worldTime-in-rangeType 1 diabetes

Substanzen

Blood GlucoseGlucoseGlycated HemoglobinHypoglycemic AgentsInsulin

Autor:innen und Institutionen

  • Medtronic, Northridge, California, USA.
  • Medtronic International Trading Sàrl, Tolochenaz, Switzerland.
  • Department of Endocrinology, Loma Linda University, Loma Linda, California, USA.
  • Department of Pediatrics, Barbara Davis Center of Childhood Diabetes, Aurora, Colorado, USA.
  • University of South Florida Diabetes and Endocrinology, Department of Pediatrics, Tampa, Florida, USA.
  • Division of Metabolism, Endocrinology and Diabetes, University of Michigan, Ann Arbor, Michigan, USA.

ORCID-Profile: Toni L Cordero, Gregory P Forlenza, Jennifer L Sherr, Robert A Vigersky

Förderung

  • NIDDK NIH HHS
  • NCATS NIH HHS

Zitieren

APA

Cordero, T. L., Dai, Z., Arrieta, A., Niu, F., Vella, M., Shin, J., Rhinehart, A. S., McVean, J., Lee, S. W., Slover, R. H., Forlenza, G. P., Shulman, D. I., Pop-Busui, R., Thrasher, J. R., Kipnes, M. S., Christiansen, M. P., Buckingham, B. A., Pihoker, C., Sherr, J. L., …, & Vigersky, R. A. (2023). Glycemic Outcomes During Early Use of the MiniMed™ 780G Advanced Hybrid Closed-Loop System with Guardian™ 4 Sensor. Diabetes Technology & Therapeutics. https://doi.org/10.1089/dia.2023.0123

Vancouver

Cordero TL, Dai Z, Arrieta A, Niu F, Vella M, Shin J, et al. Glycemic Outcomes During Early Use of the MiniMed™ 780G Advanced Hybrid Closed-Loop System with Guardian™ 4 Sensor. Diabetes Technology & Therapeutics. 2023. doi:10.1089/dia.2023.0123

BibTeX
@article{Cordero2023,
  author = {Cordero, Toni L and Dai, Zheng and Arrieta, Arcelia and Niu, Fang and Vella, Melissa and Shin, John and Rhinehart, Andrew S and McVean, Jennifer and Lee, Scott W and Slover, Robert H and Forlenza, Gregory P and Shulman, Dorothy I and Pop-Busui, Rodica and Thrasher, James R and Kipnes, Mark S and Christiansen, Mark P and Buckingham, Bruce A and Pihoker, Catherine and Sherr, Jennifer L and Kaiserman, Kevin B and Vigersky, Robert A},
  title = {Glycemic Outcomes During Early Use of the MiniMed™ 780G Advanced Hybrid Closed-Loop System with Guardian™ 4 Sensor},
  journal = {Diabetes Technology & Therapeutics},
  year = {2023},
  doi = {10.1089/dia.2023.0123}
}
Kostenlos starten →